

# indoco remedies limited

INDOCO HOUSE, 166 C. S. T. ROAD, SANTACRUZ (EAST), MUMBAI - 400 098 (INDIA) • Website : www.indoco.com PHONES : (91-22) 3386 1000 / 3386 1250 • CIN : L85190MH1947PLC005913 • GSTIN : 27AAACI0380C1Z3

December 16, 2019

То	То
Listing Department	BSE Limited
National Stock Exchange of India Limited	<b>Corporate Relationship Department</b>
'Exchange Plaza', C - 1, Block G,	1 <sup>st</sup> Floor, New Trading Ring,
Bandra-Kurla Complex,	Phiroze Jeejeebhoy Towers
<u>Bandra (E), Mumbai 400051</u> .	Dalal Street
Scrip Code: INDOCO	<u>Mumbai 400001</u>
	Scrip Code: 532612

Dear Sirs,

#### Sub: Disclosure under Regulation 30 of LODR Regulations 2015 Indoco receives EU GMP from UK-MHRA for its Sterile facility in Goa (Plant II)

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find Press Release for your information and record.

### For Indoco Remedies Limited

Jayshankar Menon Company Secretary



# **PRESS RELEASE**

## Indoco receives EU GMP from UK-MHRA for its Sterile facility in Goa (Plant II)

**December 16, 2019, Mumbai:** Indoco Remedies announced that its sterile manufacturing facility (Plant II) at Verna, Goa, has received EU GMP certification from the UK Health Regulator. This is an outcome from the last successful inspection conducted by UK MHRA from 16th to 20th September 2019.

Commenting on this positive development, **Ms. Aditi Kare Panandikar, Managing Director – Indoco Remedies Ltd. said**, "The receipt of EU GMP certification from MHRA for our sterile manufacturing unit is encouraging and reflects immense learning and adaptation of a compliant culture by our technical team."

#### About Indoco Remedies Limited:

Indoco Remedies Ltd., headquartered in Mumbai, is a fully integrated, research-oriented pharma Company with presence in 55 countries. Indoco, a USD 140 million Company, employs over 6000 people including more than 300 skilled scientists.

The Company has 9 manufacturing facilities, 6 of which are for FDFs and 3 for APIs, supported by a state-of-the-art R&D Centre and a CRO facility. The facilities have been approved by USFDA, UK-MHRA, TGA-Australia, PMDA-Japan, etc. Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. It generates more than 70 million prescriptions annually from around 3,10,000 doctors belonging to various specialties. Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments including Respiratory, Anti-Infective, Dental Care, Pain Management, Gastro-intestinal, Ophthalmic, Cardiovascular, Anti-Diabetics, Anti-Obesity, etc. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Oxipod, Cital, ATM, Cloben-G, Sensoform, Sensodent-KF, Karvol Plus, Glychek, Kidodent, Carmicide, Bactogard, etc. On the international front, Indoco has tie-ups with large generic companies like Watson (Actavis) – USA and ASPEN-South Africa.

For more details on Indoco, you may visit www.indoco.com

For Media Inquiries Please Contact: Vilas V. Nagare Mobile: 9820215745 E-mail: <u>vilasn@indoco.com</u> / <u>corpcom@indoco.com</u>